162.3 ð©º å §ç§å°ç§èåç
162.3.0.1 1ïžâ£ DGI éå¥ from Other Septic Arthritis
| ç | Pattern |
|---|---|
| DGI | äžè¯ (TST + çŽ ç¹ + polyarthralgia) æ mono purulent (knee); young, sexually active |
| S. aureus septic arthritis | mono, IDU/skin source, no TST/dermatitis |
| GAS | mono, postpartum/wound |
| Lyme arthritis | knee mono, late, endemic area |
| Reactive arthritis | post-STD/GI, 3 wk later, äžæ¯ active infection |
| Crystal (gout/CPPD) | mono, joint fluid crystals |
Workup: synovial fluid cx + NAAT + GU + pharyngeal + rectal + blood cx
162.3.0.2 2ïžâ£ Fitz-Hugh-Curtis Syndrome
- Perihepatitis (liver capsule inflammation)
- äžè ¹/RUQ ç (mimics cholecystitis)
- âViolin stringâ adhesions on laparoscopy
- N. gonorrhoeae æ Chlamydia
- Treat as PID
162.3.0.3 3ïžâ£ PID â IDSA / CDC Algorithm
- Outpatient: ceftriaxone 500 IM à 1 + doxy 100 bid à 14d + metro 500 bid à 14d
- Inpatient (TOA, pregnant, severe, fail PO): cefoxitin/cefotetan IV + doxy + ± metro
- TOA: drainage + IV antibiotic é¿æ (TOA: tubo-ovarian abscess)
162.3.0.4 4ïžâ£ MSM Screening
- CDC: q3-6 mo screening:
- Pharyngeal NAAT
- Rectal NAAT
- Urethral NAAT
- HIV + syphilis + HCV + HBV
- Triple-site testing detects asymptomatic carriage (MSM)
162.3.0.5 5ïžâ£ Doxy-PEP for STI Prophylaxis (2024)
- Doxycycline 200 mg PO within 72 hr post unprotected sex (MSM, transgender women)
- 倧 reduce N. gonorrhoeae + syphilis + chlamydia (DoxyPEP, dPEP studies)
- 2024 CDC guidance recommendation
- 泚æ: äžé© â (mixed evidence); æè¥ surveillance ongoing
162.3.0.6 6ïžâ£ Ophthalmia Neonatorum é é²
- Erythromycin 0.5% ointment universally at birth (USA)
- Taiwan: äž universal (case-by-case high-risk mother)
- é é² N. gonorrhoeae + Chlamydia conjunctivitis